01/25/23 8:27 AMNasdaq : HOTH clinical triallow floatHoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor TherapyThe initial 3 clinical sites for the Phase 2 a are located across the United States in the following cities: St Louis, MO Miami, FL Houston, TX. "We are pleased to have selected our initial clinical sites," said Robb Knie, the Company's CEO. Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and...RHEA-AIneutral
01/03/23 4:38 PMNasdaq : HOTH low floatHoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq RulesHoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth"), a patient-focused biopharmaceutical company, today announced the closing of its previously announced private placement of common stock (or pre-funded warrants in lieu thereof) and warrants toRHEA-AIneutral
12/29/22 8:00 PMNasdaq : HOTH low floatHoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq RulesHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,000,000 shares of its common stock (or common stock equivalentRHEA-AIneutral
12/29/22 8:45 AMNasdaq : HOTH low floatHoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor TherapyHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application forRHEA-AIneutral
12/01/22 10:46 AMNasdaq : HOTH low floatHoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and DrugRHEA-AIneutral
11/09/22 12:38 PMNasdaq : HOTH low floatHoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on November 9, 2022, informing the Company that it has regained compliance with theRHEA-AIneutral
10/31/22 9:57 AMNasdaq : HOTH clinical triallow floatHOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITISMEETS PRIMARY AND SECONDARY ENDPOINTS SAFETY AND EFFICACYBIOLEXA led to significant improvement in disease severity as measured by SCORAD and EASIUsing the EASI scale, 100% of patients showed clinically relevant improvement >50% compared to Day 1 during the entire 28-day study treatmentRHEA-AIneutral
10/24/22 4:15 PMNasdaq : HOTH low floatHoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on October 26,RHEA-AIneutral
09/20/22 9:05 AMNasdaq : HOTH partnershiplow floatHoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and StrokeHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announcedRHEA-AIneutral
09/06/22 8:21 AMNasdaq : HOTH low floatHoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy DisordersHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced development updates forRHEA-AIneutral